Alpha Teknova Past Earnings Performance
Past criteria checks 0/6
Alpha Teknova's earnings have been declining at an average annual rate of -68.2%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 4.4% per year.
Key information
-68.2%
Earnings growth rate
-48.5%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 4.4% |
Return on equity | -40.9% |
Net Margin | -100.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
Apr 24Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Jan 22Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Aug 14Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Apr 17Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
May 14Revenue & Expenses BreakdownBeta
How Alpha Teknova makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 37 | -37 | 35 | 6 |
30 Sep 23 | 37 | -39 | 35 | 6 |
30 Jun 23 | 39 | -52 | 36 | 7 |
31 Mar 23 | 39 | -51 | 38 | 7 |
31 Dec 22 | 41 | -47 | 37 | 8 |
30 Sep 22 | 44 | -38 | 36 | 7 |
30 Jun 22 | 42 | -19 | 33 | 7 |
31 Mar 22 | 39 | -15 | 28 | 6 |
31 Dec 21 | 37 | -10 | 24 | 4 |
30 Sep 21 | 37 | -6 | 20 | 3 |
30 Jun 21 | 37 | -3 | 16 | 2 |
31 Mar 21 | 34 | 0 | 13 | 2 |
31 Dec 20 | 31 | 1 | 10 | 2 |
31 Dec 19 | 21 | -1 | 7 | 1 |
Quality Earnings: TKNO is currently unprofitable.
Growing Profit Margin: TKNO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TKNO is unprofitable, and losses have increased over the past 5 years at a rate of 68.2% per year.
Accelerating Growth: Unable to compare TKNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TKNO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: TKNO has a negative Return on Equity (-40.85%), as it is currently unprofitable.